ArticleCureus2025
Clinical Challenges in Managing Bilateral Acute Iris Transillumination: Insights From a Case Triggered by Fluoroquinolone Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilateral acute iris transillumination (BAIT) is a rare ocular condition characterized by acute pigment dispersion from the iris pigment epithelium (IPE), resulting in diffuse iris transillumination, atonic mydriatic pupils, and intraocular hypertension. BAIT is often associated with severe photophobia and requires extended medical management. Differentiating BAIT from related conditions such as bilateral acute depigmentation of the iris (BADI) is critical, as BAIT presents with a more severe clinical course and lasting complications. Trigger factors include respiratory infections and fluoroquinolone use, particularly moxifloxacin. This report details a case of BAIT following oral moxifloxacin use. A 69-year-old male patient presented with bilateral ocular redness, pain, and severe photophobia one day after receiving an influenza vaccination and one-week post-moxifloxacin treatment. Examination revealed bullous keratopathy and bilateral iris depigmentation with transillumination. Moreover, Goldmann applanation tonometry showed an elevated intraocular pressure (IOP) exceeding 35 mmHg. Initial management included antiviral, anti-inflammatory, and IOP-lowering agents, which improved symptoms but revealed persistent pigment dispersion, atonic pupils, and recurrent IOP elevation during corticosteroid tapering. Long-term treatment with carbonic anhydrase inhibitors and alpha-adrenergic blockers stabilized IOP, but persistent iris atrophy and pigment dispersion were noted after one year. Therefore, this case underscores the severe and persistent nature of BAIT, emphasizing the importance of distinguishing it from BADI and other conditions with overlapping features. Corticosteroid management requires careful tapering to prevent symptomatic recurrences, and long-term monitoring is crucial to avoid sequelae such as glaucomatous damage. The association with moxifloxacin highlights the need for caution when prescribing fluoroquinolones, especially in at-risk populations, to mitigate potential ocular morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.